LONDON (Alliance News) - Midatech Pharma PLC on Monday said it has inked a supply agreement with Turkey's Centurion Pharma Ilac Ltd Sti for its Q-Octreotide treatment for carcinoid and acromegaly.
The agreement grants exclusive rights to Centurion for Q-Octreotide in the Turkish market. Under the agreement Midatech will receive up-front, milestone and royalty payments from Centurion. Financial terms of these payments were not disclosed.
Shares in Midatech were trading flat at 235.00 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.